Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;53(12):2231-2239.
doi: 10.1111/imj.16074. Epub 2023 Apr 18.

Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?

Nicholas Clark  1 , Michael MacIsaac  1 , Robert Little  2   3 , Sara Vogrin  1   4 , Maria Harrison  1 , Thomas Tiang  5 , James Keck  5 , Michael Johnston  5 , Georgina Cunningham  1 , Emily Wright  1 , William Connell  1   4
Affiliations

Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?

Nicholas Clark et al. Intern Med J. 2023 Dec.

Abstract

Background: In 2014, infliximab (IFX) was listed on the Australian Pharmaceutical Benefits Scheme for acute severe ulcerative colitis (ASUC) and is now the preferred option for medical salvage, superseding cyclosporin A (CsA). Optimal dosing schedules for IFX remain unknown.

Aim: The authors aim to evaluate the effect of changing from predominantly CsA to almost exclusively IFX for the treatment of steroid-refractory ASUC on colectomy rates.

Methods: A retrospective review was performed of patients admitted with ASUC between 2012 and 2020. Patients were categorised into two groups according to year of presentation - either 'historical treatment' cohort (2012-2014), when CsA was primarily used, or 'contemporary treatment' cohort (2014-2020), when IFX was mostly prescribed, in either standard or intensive doses.

Results: One hundred thirty-nine patients were included; 37 in the historical treatment cohort and 102 in the contemporary treatment cohort. In the historical treatment cohort, 12 of 37 received salvage therapy and eight (67%) received CsA. In the contemporary treatment cohort, 49 of 102 patients received salvage therapy, 40 (82%) with IFX, of whom 22 (53%) received intensified doses. Colectomy rates were similar at 30 days, 6 months and 12 months between historical and contemporary treatment cohorts (14% vs 12% [P = 0.77], 19% vs 18% [P > 0.99],and 22% vs 18% [P = 0.63], respectively). Difference in 12-month colectomy rates between standard versus intensive IFX did not meet statistical significance (three of 21 [14%] vs nine of 22 [41%]. respectively; P = 0.09).

Conclusion: There was no difference in 30-day, 6-month or 12-month colectomy rates between the historical treatment and contemporary treatment cohorts. The use of IFX, rather than CsA, even at intensified dosing, does not appear to reduce the colectomy rate observed in our patients.

Keywords: acute severe ulcerative colitis; colectomy; cyclosporin; infliximab; ulcerative colitis.

PubMed Disclaimer

References

    1. Rice-Oxley JM, Truelove S. Ulcerative colitis course and prognosis. Lancet 1950;255(6606):663-6, 666.
    1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
    1. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
    1. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87.
    1. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-6.

LinkOut - more resources